azacitidine,venetoclax
abbvie,roche
['leukemia', 'venetoclax', 'myeloid', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'azacitidine,(-oral azaci),(-azacitidine oral)', 'aza ', '+aza', 'leusm', 'viale-a', 'abbvie']
#ash22 #leusm d hner: eln 2017/2022 risk stratification and outcomes with aza/ven frontline treatment. pooled analysis of viale-a and ph1b study. total 279 a/v vs 113 a with required data. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)